Central Sensitization in Chronic Whiplash Patients
Central Sensitization in Chronic Whiplash Patients: Metabolite Concentrations in the Anterior Cingulate Cortex and Periacueductal Gray Matter
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Persistent chronic pain is a common symptom of whiplash leading to reduced quality of life. Little information is available regarding changes in brain processing areas and change in central sensitization to noxious input during the chronic phase of whiplash. Metabolite concentrations in the anterior cingulate cortex and periaqueductal gray matter may be predictors of neuropathic pain and these changes may explain the development of central sensitization in people with chronic whiplash.
Until now, there is not any study that show this approach.
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients who have suffered whiplash syndrome. By one hand, patients with chronic pain (minimun 8 weeks) and 2 points or more of pain intensity. By the other hand, patiens without pain (2 points or less of pain intensity).
By last, subjects without whiplash syndrome.
Descripción
Inclusion Criteria:
- Whiplash syndrome
- Chronic pain
- Age between 18 to 65 years
- 4 months to 2 years after the whiplash syndrome
Exclusion Criteria:
- Neurological disease
- Claustrophobia
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Grupo
- Perspectivas temporales: Transversal
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Whiplash-Pain
Subjects with chronic whiplash syndrome and pain.
The inclusion criteria for pain include the presence of daily pain during the previous 8 weeks.
Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale.
The minimum will be 2 points.
Subjects will be recruited between the 4 months until 2 years after the whiplash.
|
Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration. The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data.
Questionnaires are important to assess the chronic pain and their impact in the quality of life.
For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference.
Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain.
The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale.
Also,we will assess the disability after whiplash using the Neck Disability Index.
Conditioned Pain Modulation over the tenar eminence.
The test will be a heat tonic stimulus which evoke a 3-pain intensity.
The conditioning stimulus will be a cold water immersion (12ºC)
|
|
Whiplash-no Pain
Subjects with chronic whiplash syndrome and pain.
The inclusion criteria for pain include the ausence of daily pain during the previous 8 weeks.
Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale.
The maximun will be 2 points.
Subjects will be recruited between the 4 months until 2 years after the whiplash.
|
Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration. The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data.
Questionnaires are important to assess the chronic pain and their impact in the quality of life.
For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference.
Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain.
The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale.
Also,we will assess the disability after whiplash using the Neck Disability Index.
Conditioned Pain Modulation over the tenar eminence.
The test will be a heat tonic stimulus which evoke a 3-pain intensity.
The conditioning stimulus will be a cold water immersion (12ºC)
|
|
Non-injured
Subjects without whiplash syndrome.
The inclusion criteria are defined as a absence of previous or actual symptoms or signs of neck pain.
|
Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration. The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data.
Questionnaires are important to assess the chronic pain and their impact in the quality of life.
For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference.
Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain.
The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale.
Also,we will assess the disability after whiplash using the Neck Disability Index.
Conditioned Pain Modulation over the tenar eminence.
The test will be a heat tonic stimulus which evoke a 3-pain intensity.
The conditioning stimulus will be a cold water immersion (12ºC)
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Metabolite concentrations
Periodo de tiempo: Baseline at 0 min
|
The metabolite concentrations will be measured by magnetic resonance (spectroscopy)
|
Baseline at 0 min
|
|
Conditioned Pain Modulation
Periodo de tiempo: Baseline at 0 min
|
Conditioned Pain Modulation will be measured by a Pathway system (Medoc Ltd)
|
Baseline at 0 min
|
|
Brief Pain Inventory
Periodo de tiempo: Baseline at 0 min
|
Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference.
|
Baseline at 0 min
|
|
Neurophatic Pain Symptoms Inventory
Periodo de tiempo: Baseline at 0 min
|
Neurophatic Pain Symptoms Inventory (NPSI), it is used to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain.
|
Baseline at 0 min
|
|
Pain Catastrophizing Helplessness Subscale
Periodo de tiempo: Baseline at 0 min
|
Pain Catastrophizing Helplessness Subscale it is used to assess the catastrophizing score
|
Baseline at 0 min
|
|
Neck Disability Index
Periodo de tiempo: Baseline at 0 min
|
Neck Disability Index (NDI), it is used to assess the disability after whiplash syndrome
|
Baseline at 0 min
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Diego Serrano-Muñoz, MsC, Hospital Nacional de Parapléjicos, Toledo
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- GFSM-HNP
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .